NCT03711500 - D-serine Augmentation of Neuroplasticity | Biotech Hunter

Enrollment

45

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions

SchizophreniaSchizo Affective Disorder

Interventions

DRUG

D-serine

Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort

DRUG

Placebo

Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort

Trial Locations (2)

10032

New York State Psychiatric Institute, New York

10962

Nathan Kline Institute, Orangeburg